Advertisement

European Journal of Epidemiology

, Volume 28, Issue 7, pp 589–595 | Cite as

Clinical depression, antidepressant use and risk of future cardiovascular disease

  • Iffat RahmanEmail author
  • Keith Humphreys
  • Anna Michaela Bennet
  • Erik Ingelsson
  • Nancy Lee Pedersen
  • Patrik Karl Erik Magnusson
PSYCHIATRIC EPIDEMIOLOGY

Abstract

Many studies have shown that depression contributes to a higher risk of developing cardiovascular disease (CVD). Use of antidepressants and its association with CVD development has also been investigated previously but the results have been conflicting. Further, depression and use of antidepressants have been more widely studied in relation to coronary heart disease rather than stroke. A population-based cohort study consisting of 36,654 Swedish elderly twins was conducted with a follow-up of maximum 4 years. Information on exposures, outcomes and covariates were collected from the Swedish national patient registers, the Swedish prescribed drug registry and the Swedish twin registry. Depression and antidepressant use were both associated with CVD development. The risk was most pronounced among depressed patients who did not use antidepressants (HR 1. 48, CI 1.10–2.00). When assessing the two main CVD outcomes coronary heart disease and ischemic stroke separately, the predominant association was found for ischemic stroke while it was absent for coronary heart disease. The association between depression and stroke also remained significant when restricting to depression diagnoses occurring at least 10 years before baseline. The study supports that depression is a possible risk factor for development of CVD. Moreover, the hazard rate for CVD outcomes was highest among depressed patients who had not used antidepressants. The association with clinical depression is more marked in relation to stroke and disappears in relation to development of coronary heart disease.

Keywords

Depression Antidepressants Cardiovascular disease Epidemiology 

Notes

Acknowledgments

This work was funded by The Ministry for Higher Education, Heart and Lung Foundation No. 20070481. K.H. was supported by the Swedish Research Council (523-2006-972).

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Rutledge T, Reis SE, Olson MB, et al. Depression symptom severity and reported treatment history in the prediction of cardiac risk in women with suspected myocardial ischemia: the NHLBI-sponsored WISE study. Arch Gen Psychiatry. 2006;63:874–80.PubMedCrossRefGoogle Scholar
  2. 2.
    Wassertheil-Smoller S, Shumaker S, Ockene J, et al. Depression and cardiovascular sequelae in postmenopausal women. The Women’s Health Initiative (WHI). Arch Intern Med. 2004;164:289–98.PubMedCrossRefGoogle Scholar
  3. 3.
    Whooley MA. Depression and cardiovascular disease: healing the broken-hearted. JAMA. 2006;295:2874–81.PubMedCrossRefGoogle Scholar
  4. 4.
    Whooley MA, de Jonge P, Vittinghoff E, et al. Depressive symptoms, health behaviors, and risk of cardiovascular events in patients with coronary heart disease. JAMA. 2008;300:2379–88.PubMedCrossRefGoogle Scholar
  5. 5.
    Wouts L, Oude Voshaar RC, Bremmer MA, Buitelaar JK, Penninx BW, Beekman AT. Cardiac disease, depressive symptoms, and incident stroke in an elderly population. Arch Gen Psychiatry. 2008;65:596–602.PubMedCrossRefGoogle Scholar
  6. 6.
    Nicholson A, Kuper H, Hemingway H. Depression as an aetiologic and prognostic factor in coronary heart disease: a meta-analysis of 6362 events among 146 538 participants in 54 observational studies. Eur Heart J. 2006;27:2763–74.PubMedCrossRefGoogle Scholar
  7. 7.
    Pan A, Sun Q, Okereke OI, Rexrode KM, Hu FB. Depression and risk of stroke morbidity and mortality: a meta-analysis and systematic review. JAMA. 2011;306:1241–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Kendler KS, Gardner CO, Fiske A, Gatz M. Major depression and coronary artery disease in the Swedish twin registry: phenotypic, genetic, and environmental sources of comorbidity. Arch Gen Psychiatry. 2009;66:857–63.PubMedCrossRefGoogle Scholar
  9. 9.
    Alexopoulos GS, Meyers BS, Young RC, Campbell S, Silbersweig D, Charlson M. ‘Vascular depression’ hypothesis. Arch Gen Psychiatry. 1997;54:915–22.PubMedCrossRefGoogle Scholar
  10. 10.
    Janszky I, Ahnve S, Lundberg I, Hemmingsson T. Early-onset depression, anxiety, and risk of subsequent coronary heart disease: 37-year follow-up of 49,321 young Swedish men. J Am Coll Cardiol. 2010;56:31–7.PubMedCrossRefGoogle Scholar
  11. 11.
    Stansfeld SA, Smith GD, Marmot M. Association between physical and psychological morbidity in the Whitehall II Study. J Psychosom Res. 1993;37:227–38.PubMedCrossRefGoogle Scholar
  12. 12.
    Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 2006;27:24–31.PubMedCrossRefGoogle Scholar
  13. 13.
    Miwa K, Tanaka M, Okazaki S, et al. Association between interleukin-6 levels and first-ever cerebrovascular events in patients with vascular risk factors. Arterioscler Thromb Vasc Biol. 2013;33:400–5.PubMedCrossRefGoogle Scholar
  14. 14.
    Leonard BE, Song C. Stress and the immune system in the etiology of anxiety and depression. Pharmacol Biochem Behav. 1996;54:299–303.PubMedCrossRefGoogle Scholar
  15. 15.
    Marano G, Harnic D, Lotrionte M, et al. Depression and the cardiovascular system: increasing evidence of a link and therapeutic implications. Expert Rev Cardiovasc Ther. 2009;7:1123–47.PubMedCrossRefGoogle Scholar
  16. 16.
    Musselman DL, Evans DL, Nemeroff CB. The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment. Arch Gen Psychiatry. 1998;55:580–92.PubMedCrossRefGoogle Scholar
  17. 17.
    Roose SP. Treatment of depression in patients with heart disease. Biol Psychiatry. 2003;54:262–8.PubMedCrossRefGoogle Scholar
  18. 18.
    Blanchette CM, Simoni-Wastila L, Zuckerman IH, Stuart B. A secondary analysis of a duration response association between selective serotonin reuptake inhibitor use and the risk of acute myocardial infarction in the aging population. Ann Epidemiol. 2008;18:316–21.PubMedCrossRefGoogle Scholar
  19. 19.
    Hamer M, David Batty G, Seldenrijk A, Kivimaki M. Antidepressant medication use and future risk of cardiovascular disease: the Scottish Health Survey. Eur Heart J. 2011;32:437–42.PubMedCrossRefGoogle Scholar
  20. 20.
    Smoller JW, Allison M, Cochrane BB, et al. Antidepressant use and risk of incident cardiovascular morbidity and mortality among postmenopausal women in the Women’s Health Initiative study. Arch Intern Med. 2009;169:2128–39.PubMedCrossRefGoogle Scholar
  21. 21.
    Tata LJ, West J, Smith C, et al. General population based study of the impact of tricyclic and selective serotonin reuptake inhibitor antidepressants on the risk of acute myocardial infarction. Heart. 2005;91:465–71.PubMedCrossRefGoogle Scholar
  22. 22.
    Kimmel SE, Schelleman H, Berlin JA, et al. The effect of selective serotonin re-uptake inhibitors on the risk of myocardial infarction in a cohort of patients with depression. Br J Clin Pharmacol. 2011;72:514–7.PubMedCrossRefGoogle Scholar
  23. 23.
    Monster TB, Johnsen SP, Olsen ML, McLaughlin JK, Sorensen HT. Antidepressants and risk of first-time hospitalization for myocardial infarction: a population-based case-control study. Am J Med. 2004;117:732–7.PubMedCrossRefGoogle Scholar
  24. 24.
    Sauer WH, Berlin JA, Kimmel SE. Selective serotonin reuptake inhibitors and myocardial infarction. Circulation. 2001;104:1894–8.PubMedCrossRefGoogle Scholar
  25. 25.
    Sauer WH, Berlin JA, Kimmel SE. Effect of antidepressants and their relative affinity for the serotonin transporter on the risk of myocardial infarction. Circulation. 2003;108:32–6.PubMedCrossRefGoogle Scholar
  26. 26.
    Meier CR, Schlienger RG, Jick H. Use of selective serotonin reuptake inhibitors and risk of developing first-time acute myocardial infarction. Br J Clin Pharmacol. 2001;52:179–84.PubMedCrossRefGoogle Scholar
  27. 27.
    O’Connor CM, Jiang W, Kuchibhatla M, et al. Antidepressant use, depression, and survival in patients with heart failure. Arch Intern Med. 2008;168:2232–7.PubMedCrossRefGoogle Scholar
  28. 28.
    Zahradnik I, Minarovic I, Zahradnikova A. Inhibition of the cardiac L-type calcium channel current by antidepressant drugs. J Pharmacol Exp Ther. 2008;324:977–84.PubMedCrossRefGoogle Scholar
  29. 29.
    Pacher P, Kecskemeti V. Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns? Curr Pharm Des. 2004;10:2463–75.PubMedCrossRefGoogle Scholar
  30. 30.
    Ottervanger JP, Stricker BH, Huls J, Weeda JN. Bleeding attributed to the intake of paroxetine. Am J Psychiatry. 1994;151:781–2.PubMedGoogle Scholar
  31. 31.
    Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B. Paroxetine decreases platelet serotonin storage and platelet function in human beings. Clin Pharmacol Ther. 2000;68:435–42.PubMedCrossRefGoogle Scholar
  32. 32.
    Ludvigsson JF, Andersson E, Ekbom A, et al. External review and validation of the Swedish national inpatient register. BMC Public Health. 2011;11:450.PubMedCrossRefGoogle Scholar
  33. 33.
    Medicinalstyrelsen K. International Statistical Classification of Diseases, Injuries and Causes of Death, 1955 revision adapted for indexing of hospitals. Stockholm; 1965.Google Scholar
  34. 34.
    Socialstyrelsen. International Statistical Classification of Diseases, Injuries and Causes of Death, 1965 revision adapted for indexing of hospitals; 1968.Google Scholar
  35. 35.
    Socialstyrelsen. Svensk version av International Classification of Diseases, Ninth Revision (ICD-9); 1987.Google Scholar
  36. 36.
    Socialstyrelsen. Svensk version av International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10); 2010. Report No.: 2010-11-13.Google Scholar
  37. 37.
    Therneau TM, Grambsch PM. Modelling Survival Data: extending the Cox model: Springer; 2000.Google Scholar
  38. 38.
    Carlin JB, Galati JC, Royston P. A new framework for managing and analyzing multiply imputed data in Stata. Stata J. 2008;8:49–67.Google Scholar
  39. 39.
    Grobbee DE, Hoes AW. Confounding and indication for treatment in evaluation of drug treatment for hypertension. BMJ. 1997;315:1151–4.PubMedCrossRefGoogle Scholar
  40. 40.
    Nabi H, Kivimaki M, Suominen S, Koskenvuo M, Singh-Manoux A, Vahtera J. Does depression predict coronary heart disease and cerebrovascular disease equally well? The Health and Social Support Prospective Cohort Study. Int J Epidemiol. 2010;39:1016–24.PubMedCrossRefGoogle Scholar
  41. 41.
    Berkman LF, Blumenthal J, Burg M, et al. Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) Randomized Trial. JAMA. 2003;289:3106–16.PubMedCrossRefGoogle Scholar
  42. 42.
    van Melle JP, de Jonge P, Honig A, et al. Effects of antidepressant treatment following myocardial infarction. Br J Psychiatry. 2007;190:460–6.PubMedCrossRefGoogle Scholar
  43. 43.
    Mead GE, Hsieh CF, Lee R, et al. Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery. Cochrane Database Syst Rev. 2012;11:CD009286.PubMedGoogle Scholar
  44. 44.
    Witte TK, Timmons KA, Fink E, Smith AR, Joiner TE. Do major depressive disorder and dysthymic disorder confer differential risk for suicide? J Affect Disord. 2009;115:69–78.PubMedCrossRefGoogle Scholar
  45. 45.
    Russ TC, Stamatakis E, Hamer M, Starr JM, Kivimaki M, Batty GD. Association between psychological distress and mortality: individual participant pooled analysis of 10 prospective cohort studies. BMJ. 2012;345:e4933.PubMedCrossRefGoogle Scholar
  46. 46.
    Salmi P. Äldres behov av psykiatrisk vård och stöd; 2012 2012-02.Google Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2013

Authors and Affiliations

  • Iffat Rahman
    • 1
    Email author
  • Keith Humphreys
    • 1
  • Anna Michaela Bennet
    • 1
  • Erik Ingelsson
    • 1
  • Nancy Lee Pedersen
    • 1
  • Patrik Karl Erik Magnusson
    • 1
  1. 1.Department of Medical Epidemiology and BiostatisticsKarolinska InstitutetStockholmSweden

Personalised recommendations